Could an arthritis drug help kids with duchenne MD? new trial aims to find out
NCT ID NCT06450639
First seen Jun 24, 2026 · Last updated Aug 14, 2026 · Updated 3 times
Summary
This study tests satralizumab, a drug that calms inflammation, in 30 children aged 8 to 17 with Duchenne muscular dystrophy. The goal is to see if it improves bone density and muscle function. Participants receive injections for several months while continuing standard steroid therapy.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- satralizumab (a drug that targets inflammation)
- What this could lead to
- If successful, this could point toward a new treatment to strengthen bones and slow muscle decline in children with Duchenne muscular dystrophy.
- What could go wrong
- This is an early Phase 2 study with only 30 participants, so results may not apply to all patients. The drug may not improve bone density or muscle function as hoped.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DUCHENNE MUSCULAR DYSTROPHY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Arkansas Children's Hospital
Little Rock, Arkansas, 72202, United States
-
Child's Hosp King's Daughters
Norfolk, Virginia, 23507, United States
-
Children's Healthcare of Atlanta Center for Advanced Pediatrics
Atlanta, Georgia, 30329, United States
-
Corewell Health
Grand Rapids, Michigan, 49503, United States
-
Fondazione IRCCS Istituto Neurologico ?Carlo Besta?
Milan, Lombardy, 20133, Italy
-
Hospital Sant Joan De Deu
Esplugues de Llobregas, Barcelona, 08950, Spain
-
Hospital U. Central de Asturias
Asturias, Principality of Asturias, 33011, Spain
-
Hospital Universitario Torrecardenas;Servicio de Neurologia
Almería, 04009, Spain
-
Hospital Universitario la Fe
Valencia, 46026, Spain
-
Instytut Centrum Zdrowia Matki Polki
Lodz, 93-338, Poland
-
Lvivska oblasna tsentralna likarnia
Lviv, 79010, Ukraine
-
Neurology Rare Disease Center
Flower Mound, Texas, 75028, United States
-
Ohmatdyt - National Specialized children's hospital of MoH of Ukraine
Kyiv, 01135, Ukraine
-
Policlinico Agostino Gemelli
Rome, Lazio, 00168, Italy
-
Rigshospitalet;Klinik for Børn og Unge med Hjerne- og Nervesygdomme
København Ø, 2100, Denmark
-
University of California Davis Medical Center
Sacramento, California, 95817, United States
-
Uniwersyteckie Centrum Kliniczne
Gdansk, 80-952, Poland
-
Uniwersyteckie Centrum Kliniczne WUM, Centralny Szpital Kliniczny
Warsaw, 02-097, Poland
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a lower steroid dose preserve strength in young boys with DMD?
- Can a targeted infusion slow muscle decline in duchenne? a new trial aims to find out.
- Can a massive patient database unlock new treatments for muscular dystrophy?
- Umbilical cord stem cells aim to slow muscle loss in duchenne boys
- Experimental drug aims to preserve arm and lung function in boys with advanced duchenne
- Experimental drug KER-065 aims to slow muscle decline in duchenne muscular dystrophy